Discussion about this post

User's avatar
Janet S's avatar

Thank you for this helpful summary. I would just like to add - twenty years ago, when I started working in clinical development of a drug for RA (Actemra), Enbrel and Humira had come to market only a few years earlier. When Actemra was approved by FDA, it along with the other biologics were very expensive and still are. At the time that meant that many patients had to suffer through many unsuccessful treatment trials with methotrexate or other DMARDs before they could try a biologic. Over time, though I am now retired, I have observed a trend in rheumatology towards offering more aggressive treatment (biologics) earlier, "Treating to target" a combination of clinical signs and symptoms as well as inflammatory biomarkers (Hs-CRP and ESR) - a composite score. The idea is to induce "remission" as defined by the composite score or even "low disease activity" in order to halt the biological processes that lead to joint degradation and disability, preserving the patient's quality of life. Patients and caregivers should be aware that if they are not experiencing a good response to a new treatment, there are multiple opportunities to move on to options that may be more effective.

There could be squirrels's avatar

I spent the 1990s trying to convince doctors that something was wrong. I had pain, fatigue, random fevers, dry eyes, and other symptoms. The doctors kept telling me I was fine. And the people at my workplace never believed that I was sick. I finally was able to go to a rheumatologist without a referral. It was a relief to find out I had RA, fibromyalgia, and Sjogren’s disease and could be treated. It required a lot of persistence but I finally was heard.

Don’t let doctors brush you aside if you think there’s an issue.

5 more comments...

No posts

Ready for more?